Skip to main content
Figure 1 | Cancer Imaging

Figure 1

From: Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab

Figure 1

Non-responder to bevacizumab (PFS =36 days; OS =62 days). A) Pre-treatment, post-contrast T1-weighted image. B) Pre-treatment, Z-score normalized CBV. C) CBV atlas. D) Pre-treatment, atlas-defined hypervascular tumor tissue showing a large extent of abnormal vasculature prior to therapy. E) Post-treatment, post-contrast T1-weighted image. F) Z-score normalized CBV. G) CBV atlas. H) Post-treatment, atlas-defined hypervascular tumor tissue showing a large residual volume of abnormal vasculature after administration of bevacizumab.

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us